The DOI matches its Crossref record; 539 of the 539 references it cites were found in a registry or an index.
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Abstract
Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor agents. However, their historic classification as antimitotics does not describe all their functions. Indeed, taxanes act in a complex manner, altering multiple cellular oncogenic processes including mitosis, angiogenesis, apoptosis, inflammatory response, and ROS production. On the one hand, identification of the diverse effects of taxanes on oncogenic signaling pathways provides opportunities to apply these cytotoxic drugs in a more rational manner. On the other hand, this may facilitate the development of novel treatment modalities to surmount anticancer drug resistance. In the latter respect, chemoresistance remains a major impediment which limits the efficacy of antitumor chemotherapy. Taxanes have shown impact on key molecular mechanisms including disruption of mitotic spindle, mitosis slippage and inhibition of angiogenesis. Furthermore, there is an emerging contribution of cellular processes including autophagy, oxidative stress, epigenetic alterations and microRNAs deregulation to the acquisition of taxane resistance. Hence, these two lines of findings are currently promoting a more rational and efficacious taxane application as well as development of novel molecular strategies to enhance the efficacy of taxane-based cancer treatment while overcoming drug resistance. This review provides a general and comprehensive picture on the use of taxanes in cancer treatment. In particular, we describe the history of application of taxanes in anticancer therapeutics, the synthesis of the different drugs belonging to this class of cytotoxic compounds, their features and the differences between them. We further dissect the molecular mechanisms of action of taxanes and the molecular basis underlying the onset of taxane resistance. We further delineate the possible modalities to overcome chemoresistance to taxanes, such as increasing drug solubility, delivery and pharmacokinetics, overcoming microtubule alterations or mitotic slippage, inhibiting drug efflux pumps or drug metabolism, targeting redox metabolism, immune response, and other cellular functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Autophagy fights disease through cellular self-digestion
Mizushima, N., Levine, B., Cuervo, A. M., & Klionsky, D. J. (2008) · Nature · doi:10.1038/nature06639 · Cited by 6,452
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Reactive oxygen species in cancer
Liou, G.-Y., & Storz, P. (2010) · Free Radical Research · doi:10.3109/10715761003667554 · Cited by 3,382
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., & Heeschen, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,897
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
Prospective Identification of Tumorigenic Prostate Cancer Stem Cells
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2018 · Cited by 2,820
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Dysregulated pH: a perfect storm for cancer progression
Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3110 · Cited by 2,237
The spindle-assembly checkpoint in space and time
Musacchio, A., & Salmon, E. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2163 · Cited by 2,227
The Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,970
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Czermin, B., Melfi, R., McCabe, D., Seitz, V., Imhof, A., & Pirrotta, V. (2002) · Cell · doi:10.1016/s0092-8674(02)00975-3 · Cited by 1,533
Nita, M., & Grzybowski, A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3164734 · Cited by 1,448
Genome Regulation by Polycomb and Trithorax Proteins
Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B., & Cavalli, G. (2007) · Cell · doi:10.1016/j.cell.2007.02.009 · Cited by 1,430
Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells
Kim, M. S., Haney, M. J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N. L., Inskoe, E., Piroyan, A., Sokolsky, M., Okolie, O., et al. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.012 · Cited by 1,410
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
Expression of Multidrug Resistance Gene in Human Cancers
Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., et al. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.116 · Cited by 1,290
Schinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264
DNA breaks and chromosome pulverization from errors in mitosis
Crasta, K., Ganem, N. J., Dagher, R., Lantermann, A. B., Ivanova, E. V., Pan, Y., Nezi, L., Protopopov, A., Chowdhury, D., & Pellman, D. (2012) · Nature · doi:10.1038/nature10802 · Cited by 1,227
Regulation of an ATG7 - beclin 1 Program of Autophagic Cell Death by Caspase-8
Yu, L., Alva, A., Su, H., Dutt, P., Freundt, E., Welsh, S., Baehrecke, E. H., & Lenardo, M. J. (2004) · Science · doi:10.1126/science.1096645 · Cited by 1,220
Ditchfield, C., Johnson, V. L., Tighe, A., Ellston, R., Haworth, C., Johnson, T., Mortlock, A., Keen, N., & Taylor, S. S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208091 · Cited by 1,194
Petiot, A., Ogier-Denis, E., Blommaart, E. F. C., Meijer, A. J., & Codogno, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.2.992 · Cited by 1,164
Refined structure of αβ-tubulin at 3.5 Å resolution 1 1Edited by I. A. Wilson
Löwe, J., Li, H., Downing, K. H., & Nogales, E. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5077 · Cited by 1,145
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
Microtubules and resistance to tubulin-binding agents
Kavallaris, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2803 · Cited by 1,120
Nicolaou, K. C., Yang, Z., Liu, J. J., Ueno, H., Nantermet, P. G., Guy, R. K., Claiborne, C. F., Renaud, J., Couladouros, E. A., Paulvannan, K., et al. (1994) · Nature · doi:10.1038/367630a0 · Cited by 1,096
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Tracking the ends: a dynamic protein network controls the fate of microtubule tips
Akhmanova, A., & Steinmetz, M. O. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2369 · Cited by 1,047
Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,044
ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance
Sharom, F. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.105 · Cited by 973
P-Glycoprotein, a gatekeeper in the blood–brain barrier
Schinkel, A. H. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00085-4 · Cited by 960
Adjuvant Docetaxel for Node-Positive Breast Cancer
Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J.-P., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043681 · Cited by 954
Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4028 · Cited by 937
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Microtubule Acetylation Promotes Kinesin-1 Binding and Transport
Reed, N. A., Cai, D., Blasius, T. L., Jih, G. T., Meyhofer, E., Gaertig, J., & Verhey, K. J. (2006) · Current Biology · doi:10.1016/j.cub.2006.09.014 · Cited by 919
The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis
Carmena, M., Wheelock, M., Funabiki, H., & Earnshaw, W. C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3474 · Cited by 905
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & Forman, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840
Xu, R.-H., Pelicano, H., Zhou, Y., Carew, J. S., Feng, L., Bhalla, K. N., Keating, M. J., & Huang, P. (2005) · Cancer Research · doi:10.1158/0008-5472.613.65.2 · Cited by 835
Gascoigne, K. E., & Taylor, S. S. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.07.002 · Cited by 832
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 807
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
Flexibility in the ABC transporter MsbA: Alternating access with a twist
Ward, A., Reyes, C. L., Yu, J., Roth, C. B., & Chang, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709388104 · Cited by 771
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734
Gupta, S. C., Hevia, D., Patchva, S., Park, B., Koh, W., & Aggarwal, B. B. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4414 · Cited by 732
Mechanisms of Taxol resistance related to microtubules
Orr, G. A., Verdier-Pinard, P., McDaid, H., & Horwitz, S. B. (2003) · Oncogene · doi:10.1038/sj.onc.1206934 · Cited by 727
Albumin-bound paclitaxel: a next-generation taxane
Gradishar, W. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1041 · Cited by 712
Bulavin, D. V. (1999) · The EMBO Journal · doi:10.1093/emboj/18.23.6845 · Cited by 711
Alushin, G. M., Lander, G. C., Kellogg, E. H., Zhang, R., Baker, D., & Nogales, E. (2014) · Cell · doi:10.1016/j.cell.2014.03.053 · Cited by 696
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.
Roninson, I. B., Chin, J. E., Choi, K. G., Gros, P., Housman, D. E., Fojo, A., Shen, D. W., Gottesman, M. M., & Pastan, I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4538 · Cited by 686
Kennedy, D. O., & Wightman, E. L. (2011) · Advances in Nutrition · doi:10.3945/an.110.000117 · Cited by 684
Giannakakou, P., Sackett, D. L., Kang, Y.-K., Zhan, Z., Buters, J. T. M., Fojo, T., & Poruchynsky, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.27.17118 · Cited by 681
HIV-1 protease inhibitors. A review for clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.277.2.145 · Cited by 675
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Self-citationRole of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Kim, M. S., Haney, M. J., Zhao, Y., Yuan, D., Deygen, I., Klyachko, N. L., Kabanov, A. V., & Batrakova, E. V. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.09.011 · Cited by 663
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Self-citationStuck in Division or Passing through
Rieder, C. L., & Maiato, H. (2004) · Developmental Cell · doi:10.1016/j.devcel.2004.09.002 · Cited by 657
Kurrey, N. K., Jalgaonkar, S. P., Joglekar, A. V., Ghanate, A. D., Chaskar, P. D., Doiphode, R. Y., & Bapat, S. A. (2009) · Stem Cells · doi:10.1002/stem.154 · Cited by 655
Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together
Wang, T.-H., Wang, H.-S., & Soong, Y.-K. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11<2619::aid-cncr26>3.0.co;2-j · Cited by 647
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
Wahl, A. F., Donaldson, K. L., Faircnild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W., & Galloway, D. A. (1996) · Nature Medicine · doi:10.1038/nm0196-72 · Cited by 646
How the Warburg effect supports aggressiveness and drug resistance of cancer cells?
Icard, P., Shulman, S., Farhat, D., Steyaert, J.-M., Alifano, M., & Lincet, H. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.001 · Cited by 643
Hosios, A. M., Hecht, V. C., Danai, L. V., Johnson, M. O., Rathmell, J. C., Steinhauser, M. L., Manalis, S. R., & Vander Heiden, M. G. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.02.012 · Cited by 641
First total synthesis of taxol. 1. Functionalization of the B ring
Holton, R. A., Somoza, C., Kim, H. B., Liang, F., Biediger, R. J., Boatman, P. D., Shindo, M., Smith, C. C., & Kim, S. (1994) · Journal of the American Chemical Society · doi:10.1021/ja00083a066 · Cited by 635
Anand, S., Penrhyn-Lowe, S., & Venkitaraman, A. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00235-0 · Cited by 631
Taxol binds to polymerized tubulin in vitro
Parness, J., & Horwitz, S. (1981) · The Journal of Cell Biology · doi:10.1083/jcb.91.2.479 · Cited by 620
Singh, A., Venkannagari, S., Oh, K. H., Zhang, Y.-Q., Rohde, J. M., Liu, L., Nimmagadda, S., Sudini, K., Brimacombe, K. R., Gajghate, S., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00651 · Cited by 617
Human Multidrug-Resistant Cell Lines: Increased mdr 1 Expression Can Precede Gene Amplification
Shen, D.-W., Fojo, A., Chin, J. E., Roninson, I. B., Richert, N., Pastan, I., & Gottesman, M. M. (1986) · Science · doi:10.1126/science.3457471 · Cited by 603
Kavallaris, M., Kuo, D. Y., Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M., & Horwitz, S. B. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119642 · Cited by 601
Regulation of microtubule motors by tubulin isotypes and post-translational modifications
Sirajuddin, M., Rice, L. M., & Vale, R. D. (2014) · Nature Cell Biology · doi:10.1038/ncb2920 · Cited by 600
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition
Zhou, S.-F. (2008) · Xenobiotica · doi:10.1080/00498250701867889 · Cited by 599
Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.011 · Cited by 598
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65416 · Cited by 590
Role of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance in Cancer and Bacteria
Dharmaraja, A. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01243 · Cited by 582
Hallmarks of cancer stem cell metabolism
Sancho, P., Barneda, D., & Heeschen, C. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.152 · Cited by 574
Leith, C. P., Kopecky, K. J., Chen, I. M., Eijdems, L., Slovak, M. L., McConnell, T. S., Head, D. R., Weick, J. K., Grever, M. R., Appelbaum, F. R., et al. (1999) · PubMed · doi:10.1182/blood.v94.3.1086.415k32_1086_1099 · Cited by 573
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Targeting the PI3K signaling pathway in cancer
Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.002 · Cited by 543
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541
Taxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
The tubulin code: Molecular components, readout mechanisms, and functions
Janke, C. (2014) · Journal of Cell Biology · doi:10.1083/jcb.201406055 · Cited by 532
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Self-citationErin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
First total synthesis of taxol. 2. Completion of the C and D rings
Holton, R. A., Kim, H. B., Somoza, C., Liang, F., Biediger, R. J., Boatman, P. D., Shindo, M., Smith, C. C., & Kim, S. (1994) · Journal of the American Chemical Society · doi:10.1021/ja00083a067 · Cited by 524
Weaver, B. A. A., & Cleveland, D. W. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.011 · Cited by 520
Witta, S. E., Gemmill, R. M., Hirsch, F. R., Coldren, C. D., Hedman, K., Ravdel, L., Helfrich, B., Dziadziuszko, R., Chan, D. C., Sugita, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1988 · Cited by 515
Microtubules acquire resistance from mechanical breakage through intralumenal acetylation
Xu, Z., Schaedel, L., Portran, D., Aguilar, A., Gaillard, J., Marinkovich, M. P., Théry, M., & Nachury, M. V. (2017) · Science · doi:10.1126/science.aai8764 · Cited by 509
Sunters, A., Fernández de Mattos, S., Stahl, M., Brosens, J. J., Zoumpoulidou, G., Saunders, C. A., Coffer, P. J., Medema, R. H., Coombes, R. C., & Lam, E. W.-F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309523200 · Cited by 505
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
Self-citationTubulin acetylation protects long-lived microtubules against mechanical ageing
Portran, D., Schaedel, L., Xu, Z., Théry, M., & Nachury, M. V. (2017) · Nature Cell Biology · doi:10.1038/ncb3481 · Cited by 491
Ganta, S., & Amiji, M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800240j · Cited by 490
TLR-4 Signaling Promotes Tumor Growth and Paclitaxel Chemoresistance in Ovarian Cancer
Kelly, M. G., Alvero, A. B., Chen, R., Silasi, D.-A., Abrahams, V. M., Chan, S., Visintin, I., Rutherford, T., & Mor, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3948 · Cited by 488
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Palmeira, A., Sousa, E., H. Vasconcelos, M., & M. Pinto, M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167392 · Cited by 484
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Self-citationStructural insight into substrate and inhibitor discrimination by human P-glycoprotein
Alam, A., Kowal, J., Broude, E., Roninson, I., & Locher, K. P. (2019) · Science · doi:10.1126/science.aav7102 · Cited by 469
Noncoding RNAs in gastric cancer: implications for drug resistance
Wei, L., Sun, J., Zhang, N., Zheng, Y., Wang, X., Lv, L., Liu, J., Xu, Y., Shen, Y., & Yang, M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01185-7 · Cited by 468
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 454
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J., & Fan, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206394 · Cited by 452
Maschek, G., Savaraj, N., Priebe, W., Braunschweiger, P., Hamilton, K., Tidmarsh, G. F., De Young, L. R., & Lampidis, T. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3294 · Cited by 451
Corcoran, C., Rani, S., O’Brien, K., O’Neill, A., Prencipe, M., Sheikh, R., Webb, G., McDermott, R., Watson, W., Crown, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050999 · Cited by 448
Microtubules and Their Role in Cellular Stress in Cancer
Parker, A. L., Kavallaris, M., & McCarroll, J. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00153 · Cited by 440
Total Synthesis of Baccatin III and Taxol
Danishefsky, S. J., Masters, J. J., Young, W. B., Link, J. T., Snyder, L. B., Magee, T. V., Jung, D. K., Isaacs, R. C. A., Bornmann, W. G., Alaimo, C. A., et al. (1996) · Journal of the American Chemical Society · doi:10.1021/ja952692a · Cited by 438
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
The Binding Mode of Epothilone A on α,ß-Tubulin by Electron Crystallography
Nettles, J. H., Li, H., Cornett, B., Krahn, J. M., Snyder, J. P., & Downing, K. H. (2004) · Science · doi:10.1126/science.1099190 · Cited by 421
Extracellular vesicles: emerging targets for cancer therapy
Vader, P., Breakefield, X. O., & Wood, M. J. A. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.03.002 · Cited by 421
Chen, W.-X., Liu, X.-M., Lv, M.-M., Chen, L., Zhao, J.-H., Zhong, S.-L., Ji, M.-H., Hu, Q., Luo, Z., Wu, J.-Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095240 · Cited by 420
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement
Varma, M. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00158-0 · Cited by 418
Domingo-Domenech, J., Vidal, S. J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S. A., Rodriguez-Barrueco, R., Bonal, D. M., Charytonowicz, E., Gladoun, N., de la Iglesia-Vicente, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.016 · Cited by 416
Lai, D., Ho, K. C., Hao, Y., & Yang, X. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2711 · Cited by 416
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135406100 · Cited by 414
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
Rouzier, R., Rajan, R., Wagner, P., Hess, K. R., Gold, D. L., Stec, J., Ayers, M., Ross, J. S., Zhang, P., Buchholz, T. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408974102 · Cited by 413
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Infante, J. R., Matsubayashi, H., Sato, N., Tonascia, J., Klein, A. P., Riall, T. A., Yeo, C., Iacobuzio-Donahue, C., & Goggins, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8824 · Cited by 406
Zasadil, L. M., Andersen, K. A., Yeum, D., Rocque, G. B., Wilke, L. G., Tevaarwerk, A. J., Raines, R. T., Burkard, M. E., & Weaver, B. A. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007965 · Cited by 402
Determinants and clinical implications of chromosomal instability in cancer
Sansregret, L., Vanhaesebroeck, B., & Swanton, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.198 · Cited by 396
Zhou, M., Zhao, Y., Ding, Y., Liu, H., Liu, Z., Fodstad, O., Riker, A. I., Kamarajugadda, S., Lu, J., Owen, L. B., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-33 · Cited by 395
Chin, K. V., Tanaka, S., Darlington, G., Pastan, I., & Gottesman, M. M. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)40219-6 · Cited by 393
Transcriptional regulation of ABC drug transporters
Scotto, K. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206950 · Cited by 392
Shedden, K., Xie, X. T., Chandaroy, P., Chang, Y., & Rosania, G. R. (2003) · PubMed · Cited by 385
Microtubule dynamics in vitro are regulated by the tubulin isotype composition.
Panda, D., Miller, H. P., Banerjee, A., Ludueña, R. F., & Wilson, L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11358 · Cited by 374
Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer Cells
Zhou, Y., Tozzi, F., Chen, J., Fan, F., Xia, L., Wang, J., Gao, G., Zhang, A., Xia, X., Brasher, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1674 · Cited by 374
Liposomal paclitaxel formulations
Koudelka, Š., & Turánek, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.006 · Cited by 366
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Visconti, R., Della Monica, R., & Grieco, D. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0433-9 · Cited by 366
The proliferation rate paradox in antimitotic chemotherapy
Mitchison, T. J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-04-0335 · Cited by 363
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Kampan, N. C., Madondo, M. T., McNally, O. M., Quinn, M., & Plebanski, M. (2015) · BioMed Research International · doi:10.1155/2015/413076 · Cited by 362
The binding conformation of Taxol in β-tubulin: A model based on electron crystallographic density
Snyder, J. P., Nettles, J. H., Cornett, B., Downing, K. H., & Nogales, E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051309398 · Cited by 362
Challagundla, K. B., Wise, P. M., Neviani, P., Chava, H., Murtadha, M., Xu, T., Kennedy, R., Ivan, C., Zhang, X., Vannini, I., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv135 · Cited by 359
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Zhu, M.-L., Horbinski, C. M., Garzotto, M., Qian, D. Z., Beer, T. M., & Kyprianou, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0585 · Cited by 352
(2001) · PubMed · Cited by 350
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
Zeng, X., Sigoillot, F., Gaur, S., Choi, S., Pfaff, K. L., Oh, D.-C., Hathaway, N., Dimova, N., Cuny, G. D., & King, R. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.010 · Cited by 333
Mita, A. C., Denis, L. J., Rowinsky, E. K., DeBono, J. S., Goetz, A. D., Ochoa, L., Forouzesh, B., Beeram, M., Patnaik, A., Molpus, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0596 · Cited by 332
How do anti-mitotic drugs kill cancer cells?
Gascoigne, K. E., & Taylor, S. S. (2009) · Journal of Cell Science · doi:10.1242/jcs.039719 · Cited by 327
Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells
Aoudjit, F., & Vuori, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204554 · Cited by 325
Taxol: A novel radiation sensitizer
Tishler, R. B., Schiff, P. B., Geard, C. R., & Hall, E. J. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90888-o · Cited by 319
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318
Patil, Y., Sadhukha, T., Ma, L., & Panyam, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.021 · Cited by 317
Mitosis is not a key target of microtubule agents in patient tumors
Komlodi-Pasztor, E., Sackett, D., Wilkerson, J., & Fojo, T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.228 · Cited by 314
Nuclear envelope assembly defects link mitotic errors to chromothripsis
Liu, S., Kwon, M., Mannino, M., Yang, N., Renda, F., Khodjakov, A., & Pellman, D. (2018) · Nature · doi:10.1038/s41586-018-0534-z · Cited by 314
Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells
Janssen, A., Kops, G. J. P. L., & Medema, R. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904343106 · Cited by 313
Baloglu, E., & Kingston, D. G. I. (1999) · Journal of Natural Products · doi:10.1021/np990176i · Cited by 310
Collateral sensitivity as a strategy against cancer multidrug resistance
Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.03.002 · Cited by 305
Microtubule destabilising agents: far more than just antimitotic anticancer drugs
Bates, D., & Eastman, A. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13126 · Cited by 298
Gray, R., Bhattacharya, S., Bowden, C., Miller, K., & Comis, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6630 · Cited by 294
Burger, H., Foekens, J. A., Look, M. P., Gelder, M. E. M., Klijn, J. G. M., Wiemer, E. A. C., Stoter, G., & Nooter, K. (2003) · PubMed · Cited by 292
Regulation and Role of EZH2 in Cancer
Yamaguchi, H., & Hung, M.-C. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.3.209 · Cited by 287
Amplification and Expression of Genes Associated with Multidrug Resistance in Mammalian Cells
Scotto, K. W., Biedler, J. L., & Melera, P. W. (1986) · Science · doi:10.1126/science.2421411 · Cited by 287
Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., LoRusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2548 · Cited by 286
Taxol®: The First Microtubule Stabilizing Agent
Yang, C.-P., & Horwitz, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081733 · Cited by 284
Van der Bliek, A. M., Baas, F., Ten Houte de Lange, T., Kooiman, P. M., Van der Velde-Koerts, T., & Borst, P. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02653.x · Cited by 281
Posttranslational modifications of tubulin and the polarized transport of kinesin-1 in neurons
Hammond, J. W., Huang, C.-F., Kaech, S., Jacobson, C., Banker, G., & Verhey, K. J. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-01-0044 · Cited by 281
Meerum Terwogt, J. M., ten Bokkel Huinink, W. W., Schellens, J. H., Schot, M., Mandjes, I. A., Zurlo, M. G., Rocchetti, M., Rosing, H., Koopman, F. J., & Beijnen, J. H. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200104000-00003 · Cited by 279
Zaffaroni, N., Pennati, M., Colella, G., Perego, P., Supino, R., Gatti, L., Pilotti, S., Zunino, F., & Daidone, M. G. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8518-3 · Cited by 275
Autio, K. A., Dreicer, R., Anderson, J., Garcia, J. A., Alva, A., Hart, L. L., Milowsky, M. I., Posadas, E. M., Ryan, C. J., Graf, R. P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2168 · Cited by 275
Skurk, C., Maatz, H., Kim, H.-S., Yang, J., Abid, M. R., Aird, W. C., & Walsh, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m304736200 · Cited by 274
Extracellular vesicles and anti-cancer drug resistance
Namee, N. M., & O'Driscoll, L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.003 · Cited by 274
Lu, H., Samanta, D., Xiang, L., Zhang, H., Hu, H., Chen, I., Bullen, J. W., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513433112 · Cited by 269
Bergh, J., Bondarenko, I. M., Lichinitser, M. R., Liljegren, A., Greil, R., Voytko, N. L., Makhson, A. N., Cortes, J., Lortholary, A., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.7376 · Cited by 264
Puhr, M., Hoefer, J., Schäfer, G., Erb, H. H. H., Oh, S. J., Klocker, H., Heidegger, I., Neuwirt, H., & Culig, Z. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.08.011 · Cited by 263
Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint
Sudo, T., Nitta, M., Saya, H., & Ueno, N. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2013 · Cited by 262
Lv, M.-M., Zhu, X.-Y., Chen, W.-X., Zhong, S.-L., Hu, Q., Ma, T.-F., Zhang, J., Chen, L., Tang, J.-H., & Zhao, J.-H. (2014) · Tumor Biology · doi:10.1007/s13277-014-2377-z · Cited by 260
Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics
Gonçalves, A., Braguer, D., Kamath, K., Martello, L., Briand, C., Horwitz, S., Wilson, L., & Jordan, M. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191388598 · Cited by 260
Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., & Fais, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.004 · Cited by 259
Self-citationSynergistic blockade of mitotic exit by two chemical inhibitors of the APC/C
Sackton, K. L., Dimova, N., Zeng, X., Tian, W., Zhang, M., Sackton, T. B., Meaders, J., Pfaff, K. L., Sigoillot, F., Yu, H., et al. (2014) · Nature · doi:10.1038/nature13660 · Cited by 257
Pryor, D. E., O'Brate, A., Bilcer, G., Díaz, J. F., Wang, Y., Wang, Y., Kabaki, M., Jung, M. K., Andreu, J. M., Ghosh, A. K., et al. (2002) · Biochemistry · doi:10.1021/bi020211b · Cited by 256
Ward, A. B., Szewczyk, P., Grimard, V., Lee, C.-W., Martinez, L., Doshi, R., Caya, A., Villaluz, M., Pardon, E., Cregger, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309275110 · Cited by 256
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Dong, J., Qin, Z., Zhang, W.-D., Cheng, G., Yehuda, A. G., Ashby, C. R., Chen, Z.-S., Cheng, X.-D., & Qin, J.-J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100681 · Cited by 255
Classification Analysis of P-Glycoprotein Substrate Specificity
Didziapetris, R., Japertas, P., Avdeef, A., & Petrauskas, A. (2003) · Journal of Drug Targeting · doi:10.1080/10611860310001648248 · Cited by 253
Derry, W. B., Wilson, L., Khan, I. A., Ludueña, R. F., & Jordan, M. A. (1997) · Biochemistry · doi:10.1021/bi962724m · Cited by 252
Kwok, J. M.-M., Myatt, S. S., Marson, C. M., Coombes, R. C., Constantinidou, D., & Lam, E. W.-F. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0188 · Cited by 252
Sunters, A., Madureira, P. A., Pomeranz, K. M., Aubert, M., Brosens, J. J., Cook, S. J., Burgering, B. M. T., Coombes, R. C., & Lam, E. W.-F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1997 · Cited by 249
Energy transduction and alternating access of the mammalian ABC transporter P-glycoprotein
Verhalen, B., Dastvan, R., Thangapandian, S., Peskova, Y., Koteiche, H. A., Nakamoto, R. K., Tajkhorshid, E., & Mchaourab, H. S. (2017) · Nature · doi:10.1038/nature21414 · Cited by 248
Update on taxane development: new analogs and new formulations
Tkaczuk, K., & Yared, J. (2012) · Drug Design, Development and Therapy · doi:10.2147/dddt.s28997 · Cited by 247
Kamath, K., Wilson, L., Cabral, F., & Jordan, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414477200 · Cited by 247
Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia
Quintás-Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009) · Cancer Control · doi:10.1177/107327480901600204 · Cited by 238
Khongkow, P., Gomes, A. R., Gong, C., Man, E. P. S., Tsang, J. W.-H., Zhao, F., Monteiro, L. J., Coombes, R. C., Medema, R. H., Khoo, U. S., et al. (2016) · Oncogene · doi:10.1038/onc.2015.152 · Cited by 233
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Self-citationLi, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33282-0 · Cited by 80
Du, R., You, Q., Liu, J., Wang, C., Zhu, L., & Yang, Y. (2023) · Nano Research · doi:10.1007/s12274-023-6105-0 · Cited by 19
Metadata
- Authors
- Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 54
- Pages
- 100742
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W3120588454
- Cited by
- 385
- References
- 539
- FWCI
- 18.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.